首頁 產業/市場分類 出版商一覽 Email 通知 GII媒體代理會議 公司簡介 聯絡我們
首頁 > 市場調查報告書 > 生物科技 > 合成生物學（構成性生物學）：新興市場
產業/市場分類
生物科技 (1470)
分子標靶治療學 (51)
生技設備 (321)
生物材料 (55)
生物標記 (157)
以基因為基之藥物開發 (201)
再生醫學 (120)
抗體和免疫 (187)
個人化醫學 (54)
基因治療學和RNAi (101)
市場調查報告書

合成生物學（構成性生物學）：新興市場

Synthetic Biology: Emerging Global Markets

出版商 BCC Research
出版日期 2009年06月 商品編碼 90899
內容資訊 英文 241 pages
價格
本報告書已不再販售

本報告已在2011年11月28日停止出版。

更改為出版

合成生物學:新的全球的市場
Synthetic Biology: Emerging Global Markets
出版日期 : 2011年11月
商品編碼: 224398

簡介

2008年全球的合成生物學市場達到2億3380美元的規模。預計該市場今後將以平均每年59.8%的速度成長，2013年達到24億美元規模。

本報告書內容包括：合成生物學的技術、應用、產業動向等分析、現在的專利狀況、主要企業介紹等。本報告書內容包括：

第1章 介紹

第2章 摘要

第3章 概要

  • 本報告書中介紹的合成生物學技術
  • 何謂合成生物學？
  • 合成生物學的開發階段
  • 合成生物學市場的成長因素
  • 合成生物學產品的全球市場發展潛力
  • 合成生物學技術的生命週期
  • 合成生物學產業

第4章 合成生物學技術

  • 介紹
  • 合成生物學技術概要
  • 生物元素及整合系統技術
  • 實現技術

第5章 合成生物學的應用

  • 介紹
  • 實現技術
  • 生物元素及整合系統技術
  • 實現產品之應用
  • 消費產業別應用

第6章 合成生物學產業

  • 產業生物科技的價值鏈
  • 產業構造力學
  • 產品及技術的生命週期
  • 競爭定位
  • 基因合成產業
  • 生物燃料產業
  • 酵素產業
  • 藥品產業
  • 收購及策略聯盟
  • 生物防衛的課題
  • 產業團體

第7章 合成生物學市場

  • 促進成長因素
  • 市場預測

第8章 專利狀況

第9章 企業介紹

目錄

Abstract

This Report:

  • The global market for synthetic biology generated $233.8 million in 2008. This is expected to increase to $2.4 billion in 2013, for a compound annual growth rate (CAGR) of 59.8%.
  • The chemicals and energy segment has the largest share of the market, worth $80.6 million in 2008. This should reach $1.6 billion in 2013, for a CAGR of 81.6%.
  • The biotechnology and pharmaceuticals segment is the second-largest market segment, worth 80.3 million in 2008. This segment is projected to increase at a CAGR of 49.2% to reach $594 million in 2013.

Table of Contents

Chapter-1: SUMMARY 3

  • SUMMARY 5
  • SUMMARY TABLE GLOBAL VALUE OF SYNTHETIC BIOLOGY MARKET BY INDUSTRY, THROUGH 2013 ($ MILLIONS) 6
  • SUMMARY FIGURE GLOBAL VALUE OF SYNTHETIC BIOLOGY MARKET BY INDUSTRY, 2006-2013 ($ MILLIONS) 6
  • SUMMARY (CONTINUED) 7

Chapter-2: OVERVIEW 10

  • INTRODUCTION 18
  • DEFINITION OF SYNTHETIC BIOLOGY 18
  • TABLE 7 SYNTHETIC BIOLOGY DEFINITIONS 18
  • HISTORY OF SYNTHETIC BIOLOGY 18
  • TABLE 8 SYNTHETIC BIOLOGY HISTORY 19
  • PARADIGM SHIFT IN BIOLOGY 20
  • TABLE 9 PARADIGM SHIFT OF BIOLOGY 20
  • TABLE 10 GENETIC ENGINEERING AND SYNTHETIC BIOLOGY COMPARED 21
  • FIGURE 1 SCALE OF SYNTHETIC BIOLOGY 22
  • SYNTHETIC BIOLOGY TECHNOLOGY OVERVIEW 23
  • TABLE 11 SYNTHETIC BIOLOGY APPLICATIONS BY TECHNOLOGY 23
  • ENABLING TECHNOLOGIES 24
  • TABLE 12 IMPORTANCE OF ENABLING TECHNOLOGIES 24
  • COSTS OF DNA SYNTHESIS AND SEQUENCING 25
  • FIGURE 2 DNA SYNTHESIS AND SEQUENCING COSTS, 1990 - 2008 ($) 25
  • FIGURE 3 HUMAN GENOME SEQUENCING COSTS, 1990 - 2015 ($) 26
  • DNA SYNTHESIS TECHNOLOGIES 27
  • FIGURE 4 SIMPLIFIED SCHEMATIC OF GENE SYNTHESIS TECHNOLOGY 27
  • DNA Synthesis ... (Continued) 28
  • TABLE 13 COMPARISON OF GENE SYNTHESIS TECHNOLOGIES 29
  • PCR-Based Approaches 29
  • Solid-Phase Approaches 30
  • MICROFLUIDICS TECHNOLOGIES 31
  • TABLE 14 IMPORTANCE OF MICROFLUIDICS TECHNOLOGIES IN SYNTHETIC BIOLOGY 31
  • DNA Microarrays - Oligos Synthesis 31
  • TABLE 15 MICROARRAY TYPES 32
  • TABLE 16 DNA MICROARRAY PLATFORM FEATURES 32
  • TABLE 17 DNA MICROARRAY PLATFORM COMPARISON FOR MAJOR MANUFACTURERS 33
  • TABLE 17 (CONTINUED) 34
  • DNA Microarrays - ...(Continued) 35
  • FIGURE 5 MICROARRAYS IN GENE SYNTHESIS 36
  • DNA SEQUENCING TECHNOLOGIES 36
  • DNA Sequencing TECHNOLOGIES (continued) 37
  • FIGURE 6 SEQUENCING THROUGHPUT TREND, 1977 - 2008 38
  • FIGURE 7 DNA SEQUENCING TECHNOLOGIES 39
  • BIOINFORMATICS TECHNOLOGIES 40
  • TABLE 18 SYNTHETIC BIOLOGY BIOINFORMATICS TECHNOLOGIES 41
  • BIOLOGICAL COMPONENTS AND INTEGRATED SYSTEMS TECHNOLOGIES 41
  • TABLE 19 NUCLEIC ACIDS, GENES, AND GENOMES 41
  • SYNTHETIC GENES 42
  • TABLE 20 SYNTHETIC GENES AS MOLECULAR BIOLOGY TOOL 42
  • Synthetic Genes (Continued) 43
  • TABLE 21 SYNTHETIC GENES VERSUS PCR CLONING 44
  • BIOBRICKS/IGEM PARTS 45
  • TABLE 22 BIOBRICKS/IGEM PARTS 46
  • FIGURE 8 ROLE OF PROMOTERS AND REPORTERS IN SYNTHETIC BIOLOGY SYSTEMS 47
  • MINIMAL GENOMES AND CHASSIS ORGANISMS 48
  • TABLE 23 ATTRIBUTES OF A MINIMAL GENOME 48
  • Minimal Genomes and ... (Continued) 49
  • CASE STUDY: MINIMAL E.COLI GENOME 50
  • Role of Directed Evolution in Designing Biologic Parts 50
  • ENABLED TECHNOLOGIES 51
  • OVERVIEW 51
  • TABLE 24 ENABLED TECHNOLOGIES: EXISTING AND NEAR-TERM APPLICATIONS 51
  • Pathway Engineering 52
  • FIGURE 9 HOW SYNTHETIC BIOLOGY CREATES ENABLED PRODUCTS 52
  • TABLE 25 METABOLIC ENGINEERING FOR ARTEMISINIC ACID 53
  • Synthetic Microbial Consortia 54
  • TABLE 26 APPLICATIONS FOR SYNTHETIC MICROBIAL CONSORTIA 55
  • BIOFUELS TECHNOLOGIES 56
  • Biofuels Feedstocks 56
  • TABLE 27 ENERGY BALANCE OF SELECTED FIRST-GENERATION BIOFUEL FEEDSTOCKS 57
  • Advanced-Generation Biofuels 57
  • TABLE 28 FIRST- AND ADVANCED-GENERATION BIOFUELS COMPARED 58
  • Cellulosic Biomass 59
  • FIGURE 10 APPROXIMATE COMPOSITION OF CELLULOSIC BIOMASS (%) 59
  • TABLE 29 SYNTHETIC BIOLOGY STRATEGIES FOR CONVERTING CELLULOSIC BIOMASS INTO ETHANOL 60
  • Biofuels Types 61
  • TABLE 30 EFFICIENCY OF VARIOUS FUELS 61
  • Cellulosic Ethanol 62
  • FIGURE 11 CELLULOSIC ETHANOL PRODUCTION SCHEMATIC 62
  • TABLE 31 CORN ETHANOL COST TARGETS, 2009 ($/GAL. OF ETHANOL) 63
  • FIGURE 12 ESTIMATED 25 MGY CELLULOSIC ETHANOL PLANT COSTS (%) 64
  • Biodiesel 65
  • TABLE 32 IODINE NUMBER OF VARIOUS OILS 66
  • Other Biofuels 66
  • Role of Genetic Engineering and Synthetic Biology in Biofuels 66
  • TABLE 33 CONTRIBUTION OF SYNTHETIC BIOLOGY TO BIOFUELS 67

Chapter-3: SYNTHETIC BIOLOGY TECHNOLOGIES 50

Chapter-4: SYNTHETIC BIOLOGY APPLICATIONS 21

  • INTRODUCTION 68
  • ENABLING TECHNOLOGIES 68
  • TABLE 34 SYNTHETIC BIOLOGY PRODUCTS IMPACTED BY ENABLING TECHNOLOGIES 68
  • BIOLOGIC COMPONENTS AND INTEGRATED SYSTEMS APPLICATIONS 69
  • TABLE 35 BIOLOGICAL COMPONENTS AND INTEGRATED SYSTEMS NEAR-TERM APPLICATIONS 69
  • SYNTHETIC GENE APPLICATIONS 70
  • TABLE 36 SYNTHETIC GENES NEAR-TERM APPLICATIONS 70
  • Synthetic Gene Applications (Continued) 71
  • Synthetic Gene Applications (Continued) 72
  • BIOBRICKS/IGEM PARTS APPLICATIONS 73
  • INTEGRATED SYSTEMS APPLICATIONS 73
  • Synthetic Cells and Tissues 74
  • ENABLED PRODUCTS APPLICATIONS 75
  • TABLE 37 ENABLED PRODUCTS NEAR-TERM APPLICATIONS 75
  • APPLICATIONS BY END-USER INDUSTRY 76
  • RESEARCH AND DEVELOPMENT APPLICATIONS 76
  • TABLE 38 RESEARCH & DEVELOPMENT APPLICATIONS FOR SYNTHETIC BIOLOGY PRODUCTS 76
  • PHARMACEUTICALS APPLICATIONS 77
  • TABLE 39 DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS FOR SYNTHETIC BIOLOGY PRODUCTS 77
  • Pharmaceuticals Applications (Continued) 78
  • TABLE 40 PIPELINE OF SYNTHETIC BIOLOGY-ENABLED DRUGS 79
  • ENERGY APPLICATIONS 80
  • TABLE 41 ETHANOL AND BIODIESEL FEEDSTOCKS AND PRODUCTION PROCESSES 80
  • TABLE 42 ETHANOL AND BIODIESEL COMMON BLENDS 81
  • TABLE 43 FIRST-GENERATION FUEL ETHANOL GLOBAL PRODUCTION AND GOALS, 2007 (MILLION GALS.) 82
  • TABLE 44 FIRST-GENERATION BIODIESEL PRODUCTION AND GOALS, 2007 (MILLION GALS.) 83
  • United States 83
  • FIGURE 13 RENEWABLE FUELS STANDARDS, UNITED STATES, 2008 - 2013 (BILLION GALS./ YR) 84
  • TABLE 45 DOE FUNDING FOR CELLULOSIC BIOFUELS, 2007 - 2011 ($ MILLIONS) 85
  • Canada 86
  • Brazil 87
  • CHEMICAL INDUSTRY APPLICATIONS 87
  • Chemical Industry Applications (Continued) 88

Chapter-5: SYNTHETIC BIOLOGY INDUSTRY 43

  • INDUSTRIAL BIOTECHNOLOGY VALUE CHAIN 89
  • FIGURE 14 INDUSTRIAL BIOTECHNOLOGY VALUE CHAIN WITH SYNTHETIC BIOLOGY LEVERAGE POINTS 90
  • INDUSTRY STRUCTURAL FORCES 91
  • TABLE 46 SYNTHETIC BIOLOGY INDUSTRY STRUCTURAL FORCES 91
  • INDUSTRY STRUCTURAL FORCES (CONTINUED) 92
  • PRODUCTS AND TECHNOLOGY LIFE CYCLE 93
  • TABLE 47 SYNTHETIC BIOLOGY PRODUCTS AND TECHNOLOGY LIFE CYCLE STAGE 93
  • INDUSTRY COMPETITOR POSITIONING 94
  • TABLE 48 SYNTHETIC BIOLOGY KEY COMPETITORS BY MARKET FOCUS 95
  • GENE SYNTHESIS INDUSTRY 96
  • GENE SYNTHESIS WORKFLOW 96
  • TABLE 49 GENE SYNTHESIS WORKFLOW 96
  • Gene Synthesis Workflow (Continued) 97
  • GENE SYNTHESIS COMPETITOR STRATEGIES 98
  • FIGURE 15 SYNTHETIC GENE COMPANY ESTIMATED MARKET SHARES, 2008 (%) 99
  • Gene Synthesis ... (Continued) 100
  • TABLE 50 SYNTHETIC GENE KEY COMPETITOR STRATEGIES 101
  • Gene Synthesis ... (Continued) 102
  • Gene Synthesis Value Chain 103
  • Synthetic Gene Market Segments 104
  • Automated, Standardized Market Segment 104
  • Value-Added Market Segments 104
  • TABLE 51 GENE SYNTHESIS MARKET FACTORS OF DIFFERENTIATION 105
  • BIOFUELS INDUSTRY 106
  • COMPETITIVE DIFFERENTIATION 106
  • FEEDSTOCKS 107
  • TABLE 52 BIOFUELS: FEEDSTOCKS, PRODUCTION, AND PRODUCTS 107
  • FIGURE 16 BIOFUELS FEEDSTOCKS: RELATIVE COSTS AND VOLUMES 108
  • Sugars/Starches 108
  • Vegetable Oils 109
  • Biomass 109
  • Algae 109
  • TABLE 53 BIODIESEL YIELD OF SELECTED CROPS (GALS./ACRE/YR.) 109
  • CO2 110
  • CELLULOSIC ETHANOL INDUSTRY 111
  • TABLE 54 CELLULOSIC ETHANOL PLANTS (MGY) 111
  • Cellulosic Ethanol Industry (Continued) 112
  • BIOFUELS COMPETITOR STRATEGIES 113
  • TABLE 55 SYNTHETIC BIOLOGY-BASED BIOFUELS COMPANY STRATEGIES 114
  • TABLE 55 (CONTINUED) 115
  • Agrivida 115
  • Amyris 116
  • BP 116
  • DuPont 116
  • Gevo 116
  • LS9 117
  • Mascoma 117
  • OpX Biotechnologies 117
  • Sequesco 118
  • Solazyme 118
  • Synthetic Genomics 118
  • Verdezyne 118
  • Verenium 119
  • ROLE OF BIOFUELS FOUNDERS AND INVESTORS 119
  • TABLE 56 ROLE OF INVESTORS AND FOUNDERS IN BIOFUELS COMPANIES 119
  • ENZYMES INDUSTRY 120
  • TABLE 57 ENZYME COMPANY KEY ALLIANCES 121
  • PHARMACEUTICALS INDUSTRY 122
  • TABLE 58 PHARMACEUTICALS COMPANY STRATEGIES 122
  • INDUSTRY ACQUISITIONS AND STRATEGIC ALLIANCES 123
  • TABLE 59 INDUSTRY ACQUISITIONS, 2006 - 2008 123
  • TABLE 60 SYNTHETIC BIOLOGY STRATEGIC ALLIANCES, 2006 - 2009 124
  • TABLE 60 (CONTINUED) 125
  • TABLE 60 (CONTINUED) 126
  • BIODEFENSE ISSUES 127
  • TABLE 61 FUTURE SYNTHETIC BIOLOGY SECURITY REGULATIONS 127
  • SUPPORTING INDUSTRY ORGANIZATIONS 128
  • TABLE 62 SYNTHETIC BIOLOGY ENABLING ORGANIZATIONS 128
  • TABLE 62 (CONTINUED) 129
  • SUPPORTING INDUSTRY ... (CONTINUED) 130
  • FIGURE 17 GROWTH IN IGEM (NUMBER) 131

Chapter-6: SYNTHETIC BIOLOGY MARKETS 35

  • GROWTH DRIVING FORCES 132
  • TABLE 63 SYNTHETIC BIOLOGY GROWTH DRIVING FORCES 133
  • FIGURE 18 NIH BUDGET OUTLAYS, 2000 - 2009 ($ BILLIONS) 134
  • FIGURE 19 SYNTHETIC BIOLOGY RESEARCH PUBLICATIONS, 2000 - 2008 (NUMBER) 135
  • MARKET FORECASTS 136
  • FIGURE 20 MARKET FORECAST SCENARIO TABLE 136
  • SYNTHETIC BIOLOGY MARKETS BY INDUSTRY 137
  • Summary 137
  • TABLE 64 GLOBAL VALUE OF SYNTHETIC BIOLOGY MARKET BY END USER, THROUGH 2013 ($ MILLIONS) 137
  • R&D Market 138
  • TABLE 65 GLOBAL VALUE OF R&D MARKET BY APPLICATION, THROUGH 2013 ($ MILLIONS) 138
  • Biotechnology and Pharmaceuticals Market 139
  • TABLE 66 GLOBAL VALUE OF BIOTECHNOLOGY AND PHARMACEUTICALS MARKET BY PRODUCT TYPE, THROUGH 2013 ($ MILLIONS) 140
  • Chemicals Market 141
  • TABLE 67 GLOBAL VALUE OF CHEMICALS MARKET BY PRODUCT TYPE, THROUGH 2013 ($ MILLIONS) 141
  • Energy Market 142
  • TABLE 68 GLOBAL VALUE OF ENERGY MARKET BY PRODUCT TYPE, THROUGH 2013 ($ MILLIONS) 142
  • FIGURE 21 S-CURVE FOR SECOND-GENERATION BIOFUELS 143
  • TABLE 69 WORLD BIODIESEL PRODUCTION AND CAPACITY TRENDS, 2002 - 2008 (MILLIONS TONS/YR) 144
  • TABLE 70 GLOBAL BIOFUELS SUPPLY BY PRODUCT CLASS, THROUGH 2013 (KBOED) 145
  • FIGURE 22 GLOBAL BIOFUELS MARKET, 2013 (GALS./YR.) 145
  • FIGURE 22 (CONTINUED) 146
  • FIGURE 23 GLOBAL CELLULOSIC SECOND-GENERATION BIOFUELS MARKET, 2013 (GALS./YR) 146
  • FIGURE 23 (CONTINUED) 147
  • FIGURE 24 UNITED STATES BIOFUELS MARKET GOALS, 2022 (%) 147
  • SYNTHETIC BIOLOGY MARKETS BY PRODUCT TYPE 148
  • Summary 148
  • TABLE 71 GLOBAL VALUE OF SYNTHETIC BIOLOGY MARKET BY PRODUCT TYPE, THROUGH 2013 ($ MILLIONS) 148
  • Summary (Continued) 149
  • Enabling Products Market 150
  • TABLE 72 GLOBAL VALUE OF SYNTHETIC BIOLOGY-ENABLING PRODUCTS MARKET, THROUGH 2013 ($ MILLIONS) 150
  • Biological Parts Market 151
  • TABLE 73 GLOBAL VALUE OF DNA SYNTHESIS MARKET BY TYPE, THROUGH 2013 ($ MILLIONS) 151
  • TABLE 74 GLOBAL VALUE OF BIOLOGIC PARTS MARKET BY TYPE, THROUGH 2013 ($ MILLIONS) 152
  • Standardized Market Segment 152
  • Value-Added Market Segments 152
  • TABLE 75 GLOBAL VALUE OF BIOLOGIC PARTS MARKET BY END USER INDUSTRY, THROUGH 2013 ($ MILLIONS) 153
  • TABLE 76 GLOBAL VALUE OF BIOLOGIC PARTS BY SUPPLIER TYPE, THROUGH 2013 ($ MILLIONS) 154
  • TABLE 77 HOMEBREW VERSUS COMMERCIAL COST COMPARISON FOR SYNTHESIZING A TYPICAL 714 BP GFP GENE ($) 155
  • Integrated Systems Market 156
  • TABLE 78 GLOBAL VALUE OF SYNTHETIC BIOLOGY INTEGRATED SYSTEMS MARKET BY TYPE, THROUGH 2013 ($ MILLIONS) 156
  • Enabled Products Market 156
  • TABLE 79 GLOBAL VALUE OF SYNTHETIC BIOLOGY-ENABLED PRODUCTS MARKET BY INDUSTRY, THROUGH 2013 ($ MILLIONS) 157
  • TABLE 80 GLOBAL VALUE OF ENABLED R&D MARKET BY PRODUCT TYPE, THROUGH 2013 ($ MILLIONS) 158
  • TABLE 81 GLOBAL VALUE OF ENABLED PHARMACEUTICALS MARKET BY PRODUCT TYPE, THROUGH 2013 ($ MILLIONS) 159
  • TABLE 82 GLOBAL VALUE OF ENABLED CHEMICALS MARKET BY PRODUCT TYPE, THROUGH 2013 ($ MILLIONS) 160
  • TABLE 82 (CONTINUED) 161
  • TABLE 83 GLOBAL VALUE OF SYNTHETIC BIOLOGY-ENABLED ENERGY MARKET BY FUEL TYPE, THROUGH 2013 ($ MILLIONS) 162
  • SYNTHETIC BIOLOGY MARKET BY GEOGRAPHIC REGION 163
  • Summary 163
  • TABLE 84 GLOBAL VALUE OF SYNTHETIC BIOLOGY MARKET BY GEOGRAPHIC REGION, THROUGH 2013 ($ MILLIONS) 164
  • Importance of Geography to Fuels Markets 165
  • Importance of Geography ... (Continued) 166

Chapter-7: PATENT STATUS 13

  • INTRODUCTION 167
  • FOUNDATIONAL PATENTS 167
  • TABLE 85 SYNTHETIC BIOLOGY FOUNDATIONAL PATENTS 168
  • SYNTHETIC BIOLOGY INDUSTRY PATENT ANALYSIS 169
  • SYNTHETIC BIOLOGY INDUSTRY (continued) 170
  • FIGURE 25 NUMBER OF PATENTS BY COMPANY 171
  • FIGURE 25 (CONTINUED) 172
  • TABLE 86 PATENT DESCRIPTION BY COMPANY 173
  • FIGURE 26 SYNTHETIC BIOLOGY PATENTS BY COMPANY AND SUBCLASS (NUMBER OF PATENTS) 174
  • FIGURE 26 (CONTINUED) 175
  • LITIGATION STATUS 176
  • TABLE 87 IP LITIGATION STATUS 176
  • IP STRATEGY OF SELECTED SYNTHETIC BIOLOGY COMPANIES 177
  • METABOLIX 177
  • DUPONT 178
  • GENEART 178
  • FEBIT 179

Chapter-8: COMPANY PROFILES 66

  • AGRIVIDA 180
  • AMYRIS BIOTECHNOLOGIES, INC. 180
  • TABLE 88 AMYRIS BIODIESEL ADVANTAGES 181
  • ATG BIOSYNTHETICS GMBH 182
  • BASF AG 183
  • BIO BASIC, INC. 184
  • BIOCAT GMBH 184
  • BIONEER CORP. 185
  • BIONEXUS, INC. 185
  • BIO S&T, INC. 186
  • BIOTICA TECHNOLOGY, LTD. 186
  • BIOTICA TECHNOLOGY, LTD. (CONTINUED) 187
  • TABLE 89 STRUCTURE-FUNCTION APPROACH FOR RAPAMYCIN 188
  • TABLE 90 BIOTICA PROJECTS PIPELINE 189
  • BLUE HERON BIOTECHNOLOGIES 190
  • BRISTOL-MYERS SQUIBB 190
  • BRISTOL-MYERS SQUIBB (CONTINUED) 191
  • BRITISH PETROLEUM 192
  • CELLICON BIOTECHNOLOGIES, INC. 193
  • CODEXIS, INC. 194
  • CODON DEVICES, INC. 195
  • DANISCO A/S 195
  • DNA 2.0 196
  • TABLE 91 DNA2.0 STRATEGIC ALLIANCES 197
  • DRATHS CORP. 198
  • DUPONT 199
  • DUPONT (CONTINUED) 200
  • DYADIC INTERNATIONAL, INC. 201
  • ENTELECHON GMBH 201
  • EPOCH BIOLABS, INC. 202
  • ERAGEN BIOSCIENCES, INC. 203
  • EUROFINS MEDIGENOMIX GMBH 203
  • EUROFINS MWG OPERON 204
  • FEBIT SYNBIO GMBH 204
  • GENEART AG 205
  • TABLE 92 GENEART MAJOR STRATEGIC ALLIANCES 206
  • GENEART AG (CONTINUED) 207
  • GENEMED SYNTHESIS, INC. 208
  • GENSCRIPT CORP. 208
  • GENEWORKS PTY, LTD. 208
  • GEVO, INC. 209
  • TABLE 93 GEVO ISOBUTANOL PRODUCTION FORECAST (GALS./YR.) 209
  • HELICOS BIOSCIENCES CORP. 210
  • HELICOS BIOSCIENCES CORP. (CONTINUED) 211
  • HELICOS BIOSCIENCES CORP. (CONTINUED) 212
  • INTEGRATED DNA TECHNOLOGIES 213
  • ILLUMINA, INC. 213
  • ILLUMINA, INC. (CONTINUED) 214
  • INSTITUTE FOR ONEWORLD HEALTH 215
  • IOGEN CORP. 216
  • JOULE BIOTECHNOLOGIES, INC. 216
  • KHOSLA VENTURES 216
  • TABLE 94 KHOSLA VENTURES BIOFUELS INVESTMENT PORTFOLIO 217
  • LC SCIENCES 217
  • LIFE TECHNOLOGIES 218
  • LIFE TECHNOLOGIES (CONTINUED) 219
  • LS9, INC. 220
  • MASCOMA 221
  • TABLE 95 MASCOMA INTELLECTUAL PROPERTY STATUS 222
  • MAXYGEN 223
  • MERCK & CO. 224
  • METABOLIX, INC. 225
  • TABLE 96 METABOLOMIX BUSINESS STRATEGY 225
  • METRIGEN, INC. 226
  • NOVOZYMES A/S 227
  • OMEGA BIO-TEK, INC. 227
  • OPX BIOTECHNOLOGIES, INC. 228
  • PACIFIC BIOSCIENCES 229
  • PFIZER 230
  • PROTOLIFE SRL 231
  • QTEROS 232
  • ROCHE LIFE SCIENCES 232
  • ROCHE LIFE SCIENCES (CONTINUED) 233
  • ROYAL DSM N.V. 234
  • SANGAMO BIOSCIENCES, INC. 234
  • SANGAMO BIOSCIENCES, INC. (CONTINUED) 235
  • SANOFI AVENTIS 236
  • SCARAB GENOMICS, LLC 237
  • SEQUESCO 238
  • SLONING BIOTECHNOLOGY, GMBH 238
  • SOLAZYME, INC. 239
  • TABLE 97 SOLAZYME STRATEGIC ALLIANCES 240
  • SYNTHETIC GENOMICS 240
  • SYNTHETIC GENOMICS (CONTINUED) 241
  • TABLE 98 SYNTHETIC GENOMICS STRATEGIC ALLIANCES 242
  • VERDEZYNE 242
  • TABLE 99 VERDEZYNE STRATEGIC COLLABORATIONS 243
  • VERENIUM CORP. 244
  • VERENIUM CORP. (CONTINUED) 245
Back to Top